Stephen L. Chan

36.4k total citations · 12 hit papers
340 papers, 15.8k citations indexed

About

Stephen L. Chan is a scholar working on Hepatology, Oncology and Epidemiology. According to data from OpenAlex, Stephen L. Chan has authored 340 papers receiving a total of 15.8k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Hepatology, 150 papers in Oncology and 85 papers in Epidemiology. Recurrent topics in Stephen L. Chan's work include Hepatocellular Carcinoma Treatment and Prognosis (161 papers), Liver Disease Diagnosis and Treatment (63 papers) and Pancreatic and Hepatic Oncology Research (53 papers). Stephen L. Chan is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (161 papers), Liver Disease Diagnosis and Treatment (63 papers) and Pancreatic and Hepatic Oncology Research (53 papers). Stephen L. Chan collaborates with scholars based in Hong Kong, China and United States. Stephen L. Chan's co-authors include Paul B.S. Lai, Winnie Yeo, Frankie Mo, Masatoshi Kudo, Anthony T.�C. Chan, Vincent Wai‐Sun Wong, Bruno Sangro, Ann‐Lii Cheng, Anthony W.H. Chan and Tony Mok and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Stephen L. Chan

316 papers receiving 15.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

2014 1.8k citations Daniel H. Palmer, Paul B.S. Lai et al. Journal of Clinical Oncology profile →
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

2019 1.3k citations Richard S. Finn, Baek‐Yeol Ryoo et al. Journal of Clinical Oncology profile →
Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments

2015 505 citations Peiyong Jiang, K.C. Allen Chan et al. profile →
Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer

2017 501 citations K.C. Allen Chan, W.K. Lam et al. profile →
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

2015 493 citations Peiyong Jiang, K.C. Allen Chan et al. profile →
Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma

2019 409 citations Masatoshi Kudo, Stephen L. Chan et al. profile →
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

2020 386 citations Ann‐Lii Cheng, Chiun Hsu et al. Journal of Hepatology profile →
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

2022 259 citations Ghassan K. Abou‐Alfa, Stephen L. Chan et al. Journal of Clinical Oncology profile →
Systemic treatment of hepatocellular carcinoma: An EASL position paper

2021 243 citations Stephen L. Chan, Lorenza Rimassa et al. Journal of Hepatology profile →
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

2020 194 citations Masatoshi Kudo, Shi-Ming Lin et al. profile →
EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization.

2024 93 citations Riccardo Lencioni, Masatoshi Kudo et al. Journal of Clinical Oncology profile →
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region

2023 79 citations Stephen L. Chan, Henry Lik‐Yuen Chan et al. profile →

Peers

Countries citing papers authored by Stephen L. Chan

Since Specialization

Citations

This map shows the geographic impact of Stephen L. Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen L. Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen L. Chan more than expected).

Fields of papers citing papers by Stephen L. Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen L. Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen L. Chan. The network helps show where Stephen L. Chan may publish in the future.

Co-authorship network of co-authors of Stephen L. Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen L. Chan. A scholar is included among the top collaborators of Stephen L. Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen L. Chan. Stephen L. Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	What’s next after the 2026 BCLC update? 2025 ·Journal of Hepatology ·Landon L. Chan, Stephen L. Chan	0
2	Compassion fatigue, compassion satisfaction and mindfulness among healthcare professionals: A meta-analysis of correlational studies and randomized controlled trials 2025 ·Social Science & Medicine ·(unknown), Floria H. N. Chio, Winnie W. S. Mak, (unknown), Stephen L. Chan, Yvonne Tran, (unknown)	2
3	Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer 2025 ·Alimentary Pharmacology & Therapeutics ·(unknown), Jimmy Che‐To Lai, Landon L. Chan, Grace Lai–Hung Wong, (unknown), Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen L. Chan, Terry Cheuk‐Fung Yip	1
4	Concomitant Usage of H1‐Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival 2025 ·Cancer Medicine ·Y. H. Leung, Terry Cheuk‐Fung Yip, Grace Lai–Hung Wong, Vincent Wai‐Sun Wong, Vicki Wing‐Ki Hui, Tony Mok, Henry Lik‐Yuen Chan, Stephen L. Chan, Rashid N. Lui	0
5	Treatment for hepatocellular carcinoma after immunotherapy 2025 ·Annals of Hepatology ·Landon L. Chan, (unknown), (unknown), Stephen L. Chan	3
6	Patient-derived organoids inform pharmacogenomic vulnerabilities in liver cancer 2025 ·JHEP Reports ·Alissa M. Wong, Hao Huang, (unknown), Howard H.W. Leung, (unknown), (unknown), Xiaofan Ding, Luyao Zhang, C. H. Chu, Yue Liu, Cecilia Ka Wing Chan, Anthony W.H. Chan, Kelvin K. Ng, Xin Wang, Stephen L. Chan, Nathalie Wong	1
7	New targets and new drugs for hepatobiliary cancers 2025 ·Journal of Hepatology ·Stephen L. Chan, (unknown), Chiun Hsu, Víctor Moreno, Landon L. Chan, Bridget P. Keenan	2
8	139P KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) vs placebo (pbo) + gem/cis for patients (pts) with advanced biliary tract cancer (BTC) 2024 ·Annals of Oncology ·(unknown), Richard S. Finn, Changhoon Yoo, Zhenggang Ren, Junji Furuse, Robin Kate Kelley, Stephen L. Chan, Julien Edeline, Heinz‐Josef Klümpen, Thomas Yau, Chris Verslype, Masato Ozaka, Mohamed Bouattour, (unknown), Arndt Vogel, Juan W. Valle, Liis Starkopf, Usha Malhotra, (unknown), Shukui Qin	0
9	1238TiP Combining immunotherapy with Trop2 ADc in early stage non-small cell lung cancer (CITADEL) 2024 ·Annals of Oncology ·(unknown), (unknown), Chi‐Fai Ng, (unknown), Stephen L. Chan, (unknown), (unknown), (unknown), Ka Man Cheung, (unknown), Guiqing Liao, (unknown), (unknown), (unknown), Kin Y. Mok, Rainbow W. H. Lau, Joey Wing Yan Chan, (unknown)	0
10	Genomic origin, fragmentomics, and transcriptional properties of long cell-free DNA molecules in human plasma 2024 ·Genome Research ·Huiwen Che, Peiyong Jiang, (unknown), Suk Hang Cheng, Wenlei Peng, Rebecca W.Y. Chan, Jing Liu, Qing Zhou, W.K. Lam, Stephanie C Y Yu, (unknown), Tak Yeung Leung, John Wong, Vincent Wai‐Sun Wong, Grace Lai–Hung Wong, Stephen L. Chan, K.C. Allen Chan, Yuk Ming Dennis Lo	10
11	Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma. 2024 ·Journal of Clinical Oncology ·Stephen L. Chan, Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, Shukui Qin, Zhenggang Ren, Yasuaki Arai, В. В. Бредер, Shi-Ming Lin, Jean‐Marie Péron, Tien Quang Nguyen, Lünan Yan, Chang-Fang Chiu, Florinda Santos, (unknown), Satheesh Chiradoni Thungappa, Claire Morgan, Kerry Parsons, Ioannis Xynos, Riccardo Lencioni	4
12	Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study. 2024 ·Journal of Clinical Oncology ·Richard S. Finn, Masatoshi Kudo, Ivan Borbath, Julien Edeline, Stéphane Cattan, Hans Van Vlierberghe, Chris Verslype, Daniel H. Palmer, Per Stål, Sadahisa Ogasawara, (unknown), Mark Karwal, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, (unknown), Ken Hatogai, Abby B. Siegel, Ann‐Lii Cheng, Jean‐Luc Van Laethem	2
13	Real‐world experiences of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma in Hong Kong 2023 ·(unknown), (unknown), (unknown), Ye Feng, Stephen L. Chan	0
14	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma 2020 ·Clinical Cancer Research ·Robin Kate Kelley, Tim Meyer, Lorenza Rimassa, Philippe Merle, Joong‐Won Park, Thomas Yau, Stephen L. Chan, Jean‐Frédéric Blanc, Vincent C. Tam, Albert Tran, Vincenzo Dadduzio, David W. Markby, Rajesh Kaldate, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Ghassan K. Abou‐Alfa	66
15	Genome-Wide Screening and Functional Analysis Identifies Tumor Suppressor Long Noncoding RNAs Epigenetically Silenced in Hepatocellular Carcinoma 2019 ·Cancer Research ·Feiyue Xu, Chi Han Li, Chi Hin Wong, George Y. Chen, Paul B.S. Lai, (unknown), Stephen L. Chan, Yangchao Chen	29
16	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial breakdown → 2019 ·Journal of Clinical Oncology ·Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng, (unknown)	1300
17	Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus 2015 ·Molecular Cancer Therapeutics ·Hung Huynh, Huai-Xiang Hao, Stephen L. Chan, David Chen, Richard Ong, Khee Chee Soo, Panisa Pochanard, David T. Yang, David A. Ruddy, Manway Liu, Adnan Derti, Marissa N. Balak, Michael R. Palmer, Yan Wang, Benjamin H. Lee, Dalila Sellami, Andrew X. Zhu, Robert Schlegel, Alan Huang	60
18	A Small-Molecule Modulator of the Tumor-Suppressor miR34a Inhibits the Growth of Hepatocellular Carcinoma 2014 ·Cancer Research ·Zhangang Xiao, Chi Han Li, Stephen L. Chan, Feiyue Xu, Feng Lu, Yan Wang, (unknown), Joseph J.�Y. Sung, Christopher H.K. Cheng, Yangchao Chen	74
19	Phase I Trial of Recombinant Modified Vaccinia Ankara Encoding Epstein–Barr Viral Tumor Antigens in Nasopharyngeal Carcinoma Patients 2013 ·Cancer Research ·Edwin P. Hui, Graham S. Taylor, Hui Jia, Brigette Ma, Stephen L. Chan, Rosalie Ho, (unknown), Steven Ray Wilson, Benjamin F. Johnson, Ceri Edwards, Deborah Stocken, Alan B. Rickinson, Neil Steven, Anthony T.�C. Chan	146
20	Clinical Outcome of Atypical Endometrial Hyperplasia Diagnosed on an Endometrial Biopsy 2012 ·The American Journal of Surgical Pathology ·Emad A. Rakha, (unknown), Irshad Soomro, (unknown), Aarti Sharma, Suha Deen, Stephen L. Chan, Jafaru Abu, David Nunns, Karin Williamson, Angus McGregor, Robert Hammond, Laurence Brown	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact